Nearly two thirds of the 18 million new cancer patients each year fail treatment due to resistance that is not fully understood. Even in state-of-the-art clinical trials, oncologists struggle to select patients who are most likely to respond to specific therapies, because tools used to identify biomarkers and measure cancer resistance are outdated, imprecise, and expensive. At Aperture Bio, our single-cell proteomics technology generates rapid biomarker readouts from the most minute and fragile samples, unlocking the tumor immune environment to bring more effective therapies to market, faster.
